Sanofi to Collaborate with Google Life Sciences
to Improve Diabetes Health Outcomes
Aug 31, 2015 (9:01am EDT)
Sanofi (NYSE: SNY; EURONEXT: SAN) and the life sciences team at Google
announced that they are collaborating to improve care and outcomes for
people with type 1 and type 2 diabetes. The collaboration will pair
Sanofi's leadership in diabetes treatments and devices with Google's
expertise in analytics, miniaturized electronics and low power chip design.
The companies will explore how to improve diabetes care by developing
new tools that bring together many of the previously siloed pieces of
diabetes management and enable new kinds of interventions. This
includes health indicators such as blood glucose and hemoglobin A1c
levels, patient-reported information, medication regimens and sensor
devices.
Sanofi and the life sciences team at Google will combine their respective
expertise in science and technology to work on better ways to collect,
analyze and understand multiple sources of information impacting
diabetes. The hope is that it will be easier for patients to successfully
manage their diabetes, which would reduce the risk of complications,
improve outcomes and ultimately lower costs.
"As a global leader in diabetes care, we have both an obligation and a
commitment to provide integrated solutions for people living with
diabetes," said Olivier Brandicourt, MD, Chief Executive Officer, Sanofi.
"This initiative combines Sanofi's strength and knowledge in diabetes with
Google's leadership in technology and analytics to create a first-of-its-kind
initiative with the potential to transform diabetes care."
"With new technologies emerging to provide a more continuous and
real-time view of a patient's health, we can see the promise for more
proactive and effective ways to control diabetes," said Andy Conrad, CEO
of the life sciences team at Google. "Together with Sanofi, we believe
diabetes management can be simpler and more convenient, which may
help patients achieve an improved quality of life."
"We have built expertise in providing holistic, integrated solutions that
combine medicines, devices, technologies and services," said Pascale
Witz, Executive Vice President, Sanofi, who will lead the Global Diabetes
and Cardiovascular Care Business Unit in the company's new
organizational structure. "The life sciences team at Google can help us
improve the patient experience, outcomes and manage health care costs
more effectively."
"We are experiencing a worldwide pandemic of diabetes, and it's very
encouraging to see health care and technology innovators step up to the
challenge of providing cutting edge tools and care advancing technologies
to help people with diabetes manage their disease, 24/7," said John L.
Brooks, III, President and CEO of Joslin Diabetes Center, which is a
partner to the collaboration. "Technology, sensors, analytics, and digital
solutions will revolutionize how blood sugars are managed, which will
deliver improved quality of life, lowering the risk of complications and
reducing the costs and barriers associated with diabetes care. Ultimately,
I truly hope we're able to turn the Joslin Diabetes Center into a museum."
About Diabetes
Diabetes mellitus, or simply diabetes, is a chronic disease that occurs
when the pancreas is no longer able to make insulin, or when the body
cannot make good use of the insulin it produces. Insulin is a hormone
made by the pancreas that acts like a key to let glucose from the food we
eat pass from the blood stream into the cells in the body to produce
energy. All carbohydrate foods are broken down into glucose in the blood.
Insulin helps glucose get into the cells.[1]
Not being able to produce insulin or use it effectively leads to raised
glucose levels in the blood (known as hyperglycemia). Over the long-term
high glucose levels are associated with damage to the body and failure of
various organs and tissues.[2]
The latest edition IDF Diabetes Atlas, published on World Diabetes Day,
estimates that people living with diabetes will surge from 382 million to
592 million people by 2035.[3]
About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes
by delivering innovative, integrated and personalized solutions. Driven by
valuable insights that come from listening to and engaging with people
living with diabetes, the Company is forming partnerships to offer
diagnostics, therapies, services, and devices including blood glucose
monitoring systems. Sanofi markets injectable, inhaled and oral
medications for people with type 1 or type 2 diabetes.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core
strengths in diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and Genzyme.
Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
About the life sciences team at Google
The life sciences team at Google is focused on helping to move health
care from reactive to proactive. Combining expertise from the fields of
biology, chemistry, physics, medicine, electrical engineering, computer
science, we're developing new technology tools for physicians that can
integrate easily into daily life and help transform the detection,
prevention, and management of disease. Current projects in development
include a smart contact lens with miniaturized glucose sensor; a
nanodiagnostics platform to help with early detection of disease; and
Liftware utensils for people with tremor.
 | |  | |  | |  | |  |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
 | |  | |  | |  | |  | |  |
 | |  | |  | |  | |  | |  |
